VAERS reports by lot

Pfizer COVID-19 lot GH9697: VAERS reports

345 VAERS reports list lot GH9697 as a Pfizer COVID-19 vaccine, received between 2022-10-10 and 2024-12-16. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
345
Reports
19%
Marked serious
3
With a death outcome
21
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)33026%
Cardiac / Cardiovascular20316%
Respiratory17413%
Gastrointestinal15912%
Neurological13911%
Thrombotic / Hematological584%
Musculoskeletal564%
Injection-site / Local reaction494%
Dermatological (non-injection-site)433%
Allergic / Anaphylactic353%
Psychiatric / Neuropsychiatric272%
Reproductive / Menstrual91%
Autoimmune / Immune-mediated81%

Where reports came from

U.S. state of the reporter, where given (top 12).

Arizona29
Washington23
California20
Ohio18
Oklahoma14
Texas12
New York12
Michigan11
New Jersey11
Minnesota11
Wisconsin10
Florida10

Reports by month received

2022-1053
2022-1166
2022-1257
2023-0133
2023-0217
2023-0320
2023-0430
2023-0516
2023-0617
2023-0712
2023-085
2023-091
2023-107
2023-112
2023-121
2024-011
2024-021
2024-041
2024-051
2024-102
2024-122

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.